Natalizumab Significantly Improves Cognitive Impairment over Three Years in MS: Pattern of Disability Progression and Preliminary MRI Findings

Previous studies reported that Multiple Sclerosis (MS) patients treated with natalizumab for one or two years exhibit a significant reduction in relapse rate and in cognitive impairment, but the long term effects on cognitive performance are unknown. This study aimed to evaluate the effects of natal...

Descripción completa

Detalles Bibliográficos
Autores principales: Mattioli, Flavia, Stampatori, Chiara, Bellomi, Fabio, Scarpazza, Cristina, Capra, Ruggero
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4492934/
https://www.ncbi.nlm.nih.gov/pubmed/26148120
http://dx.doi.org/10.1371/journal.pone.0131803

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4492934/
https://www.ncbi.nlm.nih.gov/pubmed/26148120
http://dx.doi.org/10.1371/journal.pone.0131803

Ejemplares similares